These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7715225)

  • 41. Effect of heparin reversal and fresh platelet transfusion on platelet emboli post-cardiopulmonary bypass in a pig model.
    Dewanjee MK; Wu SM; Hsu LC
    ASAIO J; 2000; 46(3):313-8. PubMed ID: 10826743
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans.
    Dehmer GJ; Fisher M; Tate DA; Teo S; Bonnem EM
    Circulation; 1995 Apr; 91(8):2188-94. PubMed ID: 7697848
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?
    Teoh KH; Young E; Blackall MH; Roberts RS; Hirsh J
    J Thorac Cardiovasc Surg; 2004 Aug; 128(2):211-9. PubMed ID: 15282457
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Attenuation of hemodynamic and hematologic effects of heparin-protamine sulfate interaction after aortic reconstruction in a canine model.
    Wakefield TW; Lindblad B; Whitehouse WM; Hantler CB; Stanley JC
    Surgery; 1986 Jul; 100(1):45-51. PubMed ID: 3726760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.
    Fareed J; Walenga JM; Pifarre R; Hoppensteadt D; Koza M
    Haemostasis; 1991; 21 Suppl 1():64-72. PubMed ID: 1894198
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protamine reduces whole blood platelet aggregation after cardiopulmonary bypass.
    Olsson A; Alfredsson J; Håkansson E; Svedjeholm R; Berglund J; Berg S
    Scand Cardiovasc J; 2016; 50(1):58-63. PubMed ID: 26402229
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation.
    Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Tejwani S; Hulin MS; Stanley JC
    J Surg Res; 1996 Jun; 63(1):280-6. PubMed ID: 8661211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interaction of heparin and protamine in presence of overdosage: in vitro study.
    Hanke AA; Severloh I; Flöricke F; Weber CF; Lang T
    Asian Cardiovasc Thorac Ann; 2021 Jan; 29(1):5-9. PubMed ID: 32854516
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heparin and Protamine Titration Does Not Improve Haemostasis after Cardiac Surgery: A Prospective Randomized Study.
    Radulovic V; Laffin A; Hansson KM; Backlund E; Baghaei F; Jeppsson A
    PLoS One; 2015; 10(7):e0130271. PubMed ID: 26134993
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of the effect of varying protamine-to-heparin ratio on coagulation in vitro.
    Ho LTS; McVey MJ; Kuiper GJAJM; Gross PL; Karkouti K
    Br J Anaesth; 2021 Oct; 127(4):e128-e130. PubMed ID: 34334192
    [No Abstract]   [Full Text] [Related]  

  • 51. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.
    Chang LC; Lee HF; Chung MJ; Yang VC
    Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of methylprednisolone on complement activation during heparin neutralization.
    Loubser PG
    J Cardiovasc Pharmacol; 1997 Jan; 29(1):23-7. PubMed ID: 9007666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of a heparin removal device: a prospective randomized preclinical outcomes study.
    Zwischenberger JB; Tao W; Deyo DJ; Vertrees RA; Alpard SK; Shulman G
    Ann Thorac Surg; 2001 Jan; 71(1):270-7. PubMed ID: 11216760
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hemostatic effects of low-dose protamine following cardiopulmonary bypass.
    Miyashita T; Nakajima T; Hayashi Y; Kuro M
    Am J Hematol; 2000 Jun; 64(2):112-5. PubMed ID: 10814990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of excess protamine on thrombelastography in vitro.
    Gibbs NM; Yim D; Weightman W; Sheminant M; Rowe R
    Anaesth Intensive Care; 2006 Oct; 34(5):579-85. PubMed ID: 17061631
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pilot validation of an individualised pharmacokinetic algorithm for protamine dosing after systemic heparinisation for cardiopulmonary bypass.
    Miles LF; Marchiori P; Falter F
    Perfusion; 2017 Sep; 32(6):481-488. PubMed ID: 28820026
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Restoration of the normal coagulation process: advances in therapies to antagonize heparin.
    D'Ambra M
    J Cardiovasc Pharmacol; 1996; 27 Suppl 1():S58-62. PubMed ID: 8938285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
    Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
    Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pulmonary microvascular responses to protamine and histamine. Effects of cardiopulmonary bypass.
    Friedman M; Johnson RG; Wang SY; Dai HB; Thurer RL; Weintraub RM; Sellke FW
    J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1092-9. PubMed ID: 7983878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.